| Q73739388 | Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women |
| Q54573717 | CHAPTER 7 Methods for detection of HPV infection and its clinical utility. |
| Q36584420 | Chapter 5: Updating the natural history of HPV and anogenital cancer |
| Q79195094 | Contribution of high risk human papillomavirus testing to the management of premalignant and malignant lesions of the uterine cervix |
| Q35792128 | Detection of Genomic Amplification of the Human Telomerase Gene (TERC) in Cytologic Specimens as a Genetic Test for the Diagnosis of Cervical Dysplasia |
| Q45280381 | Detection of high risk human papillomavirus by hybrid capture II® according cytological findings in women treated for squamous intraepithelial lesions of the cervix, period 2006/2010 |
| Q33826637 | Downregulation of Cdc2/CDK1 kinase activity induces the synthesis of noninfectious human papillomavirus type 31b virions in organotypic tissues exposed to benzo[a]pyrene |
| Q41753328 | Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study |
| Q39635628 | Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. |
| Q34186555 | Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results |
| Q24675639 | Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer |
| Q44359880 | High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older |
| Q43610107 | High-risk human papilloma virus infection of the foreskin in asymptomatic boys |
| Q81404025 | Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial |
| Q54023273 | Human papillomavirus and cervical cancer |
| Q60441068 | Human papillomavirus infections |
| Q35627584 | Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine |
| Q37334772 | Kinetics of DNA load predict HPV 16 viral clearance. |
| Q34176414 | Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence |
| Q36494175 | Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening |
| Q80439545 | Population-based study of human papillomavirus infection and cervical neoplasia in Athens, Greece |
| Q37699247 | Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development |
| Q46087962 | Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system |
| Q84615567 | Significance of High-Risk Human Papillomavirus DNA Detection in Women 50 Years and Older With Squamous Cell Papanicolaou Test Abnormalities |
| Q35075785 | Translational approaches to improving cervical screening |
| Q58302484 | Understanding Human Papillomavirus |
| Q82633620 | Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening |
| Q81319596 | Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests |
| Q38216073 | Worldwide incidence of cervical lesions: a systematic review. |